Xcell buys Visiomed to speed access to skin cancer market
This article was originally published in Clinica
Executive Summary
Australian company Xcell Diagnostics plans to buy Visiomed, of Bochum, Germany, which has developed the microDERM computer-based system to help in the diagnosis and management of skin cancer. Xcell is paying Aus$1.5m ($0.8m) cash, as well as shares, options and royalties.